An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
01 07 2019
Historique:
received: 23 08 2018
accepted: 24 05 2019
entrez: 3 7 2019
pubmed: 3 7 2019
medline: 26 9 2019
Statut: epublish

Résumé

Dysregulation of histone modifications promotes carcinogenesis by altering transcription. Breast cancers frequently overexpress the histone methyltransferase EZH2, the catalytic subunit of Polycomb Repressor Complex 2 (PRC2). However, the role of EZH2 in this setting is unclear due to the context-dependent functions of PRC2 and the heterogeneity of breast cancer. Moreover, the mechanisms underlying PRC2 overexpression in cancer are obscure. Here, using multiple models of breast cancer driven by the oncogene ErbB2, we show that the tyrosine kinase c-Src links energy sufficiency with PRC2 overexpression via control of mRNA translation. By stimulating mitochondrial ATP production, c-Src suppresses energy stress, permitting sustained activation of the mammalian/mechanistic target of rapamycin complex 1 (mTORC1), which increases the translation of mRNAs encoding the PRC2 subunits Ezh2 and Suz12. We show that Ezh2 overexpression and activity are pivotal in ErbB2-mediated mammary tumourigenesis. These results reveal the hitherto unknown c-Src/mTORC1/PRC2 axis, which is essential for ErbB2-driven carcinogenesis.

Identifiants

pubmed: 31263101
doi: 10.1038/s41467-019-10681-4
pii: 10.1038/s41467-019-10681-4
pmc: PMC6603039
doi:

Substances chimiques

Adenosine Triphosphate 8L70Q75FXE
EZH2 protein, human EC 2.1.1.43
Enhancer of Zeste Homolog 2 Protein EC 2.1.1.43
Polycomb Repressive Complex 2 EC 2.1.1.43
ERBB2 protein, human EC 2.7.10.1
Receptor, ErbB-2 EC 2.7.10.1
CSK Tyrosine-Protein Kinase EC 2.7.10.2
src-Family Kinases EC 2.7.10.2
CSK protein, human EC 2.7.10.23
Mechanistic Target of Rapamycin Complex 1 EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

2901

Subventions

Organisme : NCI NIH HHS
ID : K00 CA212221
Pays : United States
Organisme : NCI NIH HHS
ID : F99 CA212221
Pays : United States
Organisme : United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (CDMRP)
ID : W81XWH-11-1-0046
Pays : International
Organisme : CIHR
Pays : Canada
Organisme : NIDDK NIH HHS
ID : K25 DK115904
Pays : United States
Organisme : Terry Fox Research Institute (Institut de Recherche Terry Fox)
ID : 1048
Pays : International

Références

Nat Commun. 2018 Jun 29;9(1):2547
pubmed: 29959321
Cell Cycle. 2016 Sep;15(17):2256-62
pubmed: 27419533
Cancer Metab. 2013 Aug 14;1(1):18
pubmed: 24280377
Genome Res. 2016 May;26(5):636-48
pubmed: 26984228
Biochem J. 2012 Oct 15;447(2):281-9
pubmed: 22823520
Int J Cancer. 2016 Feb 1;138(3):747-57
pubmed: 26284485
EMBO J. 2008 Mar 19;27(6):910-20
pubmed: 18273058
Mol Oncol. 2012 Oct;6(5):494-506
pubmed: 22766277
Genes Dev. 2015 Dec 15;29(24):2547-62
pubmed: 26637281
Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106
Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):8977-82
pubmed: 22611195
Clin Cancer Res. 2016 Jul 1;22(13):3249-59
pubmed: 26842237
Int J Cancer. 2007 Mar 1;120(5):995-1004
pubmed: 17131343
Trends Cell Biol. 2016 Dec;26(12):918-933
pubmed: 27426745
BMC Bioinformatics. 2013 Apr 15;14:128
pubmed: 23586463
Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11
pubmed: 14500907
Biochem J. 2010 Jan 27;426(1):109-18
pubmed: 19958286
J Biol Chem. 2003 May 2;278(18):15789-93
pubmed: 12600984
Mol Cell. 2008 Apr 25;30(2):214-26
pubmed: 18439900
Nature. 2012 Dec 6;492(7427):108-12
pubmed: 23051747
Nat Commun. 2018 Oct 19;9(1):4351
pubmed: 30341294
Bioinformatics. 2011 May 15;27(10):1440-1
pubmed: 21422072
Mol Cell. 2008 Nov 21;32(4):491-502
pubmed: 19026780
Nature. 2012 Feb 22;485(7396):55-61
pubmed: 22367541
J Vis Exp. 2014 May 17;(87):
pubmed: 24893926
Oncogene. 2011 Sep 29;30(39):4118-28
pubmed: 21499305
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Mol Cell Biol. 2009 Nov;29(21):5858-71
pubmed: 19704002
Nature. 2011 Jan 20;469(7330):343-9
pubmed: 21248841
Cell Metab. 2018 Dec 4;28(6):833-847.e8
pubmed: 30174304
Elife. 2016 Jan 27;5:
pubmed: 26814573
Curr Opin Cell Biol. 2015 Apr;33:1-7
pubmed: 25259783
Mol Carcinog. 2015 Oct;54(10):1172-80
pubmed: 25043748
J Biol Chem. 2012 Nov 9;287(46):38625-36
pubmed: 23027865
Mol Cell Biol. 2001 Jun;21(12):3995-4004
pubmed: 11359907
Science. 1994 Mar 18;263(5153):1609-12
pubmed: 8128248
Cell Rep. 2013 Feb 21;3(2):411-26
pubmed: 23375371
Mol Cell. 2016 Jun 2;62(5):695-711
pubmed: 27259202
Proc Natl Acad Sci U S A. 2013 May 7;110(19):7922-7
pubmed: 23620515
Br J Cancer. 2006 Nov 20;95(10):1410-4
pubmed: 17060931
Nat Rev Cancer. 2016 Dec;16(12):803-810
pubmed: 27658528
Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1415-20
pubmed: 9990038
Cancer Metab. 2013 Dec 05;1(1):22
pubmed: 24304688
Nat Cell Biol. 2015 Oct;17(10):1304-16
pubmed: 26322680
J Immunol. 2005 Jan 1;174(1):180-94
pubmed: 15611240
Cell Metab. 2010 May 5;11(5):390-401
pubmed: 20444419
Mol Cell. 1999 Dec;4(6):915-24
pubmed: 10635317
Science. 2009 May 22;324(5930):1076-80
pubmed: 19461003
Histopathology. 2016 Jul;69(1):25-34
pubmed: 26588661
Cell Metab. 2013 Nov 5;18(5):698-711
pubmed: 24206664
J Cell Sci. 2008 Mar 15;121(Pt 6):804-13
pubmed: 18285444
Cancer Metab. 2014 Aug 28;2:12
pubmed: 25184038
Cell. 2003 Nov 26;115(5):577-90
pubmed: 14651849
Cancer Res. 2007 Nov 15;67(22):10804-12
pubmed: 18006825
Nature. 2007 Nov 29;450(7170):736-40
pubmed: 18046414
Nat Cell Biol. 2015 Apr;17(4):351-9
pubmed: 25774832
J Med Chem. 2016 May 26;59(10):4697-710
pubmed: 27115835
Cancer Cell. 2016 Apr 11;29(4):548-562
pubmed: 27052953
Nucleic Acids Res. 2015 Oct 15;43(18):8774-89
pubmed: 26250110
Biochem J. 2000 Jun 15;348 Pt 3:607-14
pubmed: 10839993
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2808-13
pubmed: 21628573
Br J Cancer. 2009 Jan 13;100(1):123-33
pubmed: 19066611
Nature. 1994 Oct 27;371(6500):762-7
pubmed: 7935836
Mol Cell. 2016 Dec 15;64(6):1074-1087
pubmed: 27889452
Nat Commun. 2017 Jan 05;8:13732
pubmed: 28054552
J Biol Chem. 2002 May 3;277(18):15813-8
pubmed: 11867640
Biochim Biophys Acta. 2012 May;1817(5):718-25
pubmed: 22321370
Leukemia. 2017 Nov;31(11):2326-2335
pubmed: 28280275
Nat Methods. 2009 Apr;6(4):275-7
pubmed: 19305406
PLoS One. 2016 Nov 22;11(11):e0166438
pubmed: 27875550
Stem Cells. 2013 Sep;31(9):1910-20
pubmed: 23712803
Mol Cell Biol. 2007 May;27(10):3769-79
pubmed: 17339329

Auteurs

Harvey W Smith (HW)

Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montréal, QC, H3A 1A3, Canada.
Department of Biochemistry, McGill University, Montréal, QC, H3A 1A3, Canada.

Alison Hirukawa (A)

Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montréal, QC, H3A 1A3, Canada.
Department of Biochemistry, McGill University, Montréal, QC, H3A 1A3, Canada.

Virginie Sanguin-Gendreau (V)

Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montréal, QC, H3A 1A3, Canada.
Department of Biochemistry, McGill University, Montréal, QC, H3A 1A3, Canada.

Ipshita Nandi (I)

Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montréal, QC, H3A 1A3, Canada.
Department of Biochemistry, McGill University, Montréal, QC, H3A 1A3, Canada.

Catherine R Dufour (CR)

Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montréal, QC, H3A 1A3, Canada.
Department of Biochemistry, McGill University, Montréal, QC, H3A 1A3, Canada.

Dongmei Zuo (D)

Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montréal, QC, H3A 1A3, Canada.
Department of Biochemistry, McGill University, Montréal, QC, H3A 1A3, Canada.

Kristofferson Tandoc (K)

Lady Davis Institute for Medical Research, McGill University, Montréal, QC, H3T 1E2, Canada.

Matthew Leibovitch (M)

Lady Davis Institute for Medical Research, McGill University, Montréal, QC, H3T 1E2, Canada.

Salendra Singh (S)

Case Comprehensive Cancer Center, Case Western University, Cleveland, OH, 44145, USA.

Jonathan P Rennhack (JP)

Department of Physiology, Michigan State University, East Lansing, MI, 48824, USA.

Matthew Swiatnicki (M)

Department of Physiology, Michigan State University, East Lansing, MI, 48824, USA.

Cynthia Lavoie (C)

Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montréal, QC, H3A 1A3, Canada.
Department of Biochemistry, McGill University, Montréal, QC, H3A 1A3, Canada.

Vasilios Papavasiliou (V)

Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montréal, QC, H3A 1A3, Canada.
Department of Biochemistry, McGill University, Montréal, QC, H3A 1A3, Canada.

Carolin Temps (C)

Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XR, UK.

Neil O Carragher (NO)

Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XR, UK.

Asier Unciti-Broceta (A)

Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XR, UK.

Paul Savage (P)

Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montréal, QC, H3A 1A3, Canada.
Department of Medicine, McGill University, Montréal, QC, H3A 1A3, Canada.

Mark Basik (M)

Case Comprehensive Cancer Center, Case Western University, Cleveland, OH, 44145, USA.
Department of Medicine, McGill University, Montréal, QC, H3A 1A3, Canada.
Department of Surgery, McGill University, Montréal, QC, H3A 1A3, Canada.

Vincent van Hoef (V)

Department of Oncology-Pathology, Science for Life Laboratory, Karolinska Institute, Stockholm, 171 76, Sweden.

Ola Larsson (O)

Department of Oncology-Pathology, Science for Life Laboratory, Karolinska Institute, Stockholm, 171 76, Sweden.

Caroline L Cooper (CL)

Department of Anatomical Pathology, Pathology Queensland, Princess Alexandra Hospital, Woolloongabba, QLD, 4102, Australia.
PA Southside Clinical School, School of Medicine, University of Queensland, Brisbane, QLD, 4102, Australia.

Ana Cristina Vargas Calderon (AC)

Douglass Hanly Moir Pathology, Macquarie Park, NSW, 2113, Australia.

Jane Beith (J)

Chris O'Brien Lifehouse, Camperdown, NSW, 2050, Australia.
Sydney Medical School, University of Sydney, Sydney, NSW, 2006, Australia.

Ewan Millar (E)

Department of Anatomical Pathology, South Eastern Area Laboratory Service, St George Public Hospital, Kogarah, NSW, 2217, Australia.
School of Medicine and Health Sciences, University of Western Sydney, Campbelltown, NSW, 2560, Australia.
Faculty of Medicine, University of New South Wales, Kensington, NSW, 2052, Australia.

Christina Selinger (C)

Dept of Tissue Pathology and Diagnostic Oncology, Royal Prince Albert Hospital, Camperdown, NSW, 2050, Australia.

Vincent Giguère (V)

Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montréal, QC, H3A 1A3, Canada.
Department of Biochemistry, McGill University, Montréal, QC, H3A 1A3, Canada.
Department of Medicine, McGill University, Montréal, QC, H3A 1A3, Canada.
Department of Oncology, McGill University, Montréal, QC, H3A 1A3, Canada.

Morag Park (M)

Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montréal, QC, H3A 1A3, Canada.
Department of Biochemistry, McGill University, Montréal, QC, H3A 1A3, Canada.
Department of Medicine, McGill University, Montréal, QC, H3A 1A3, Canada.
Department of Oncology, McGill University, Montréal, QC, H3A 1A3, Canada.

Lyndsay N Harris (LN)

Case Comprehensive Cancer Center, Case Western University, Cleveland, OH, 44145, USA.
Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Rockville, MD, 20890, USA.

Vinay Varadan (V)

Case Comprehensive Cancer Center, Case Western University, Cleveland, OH, 44145, USA.

Eran R Andrechek (ER)

Department of Physiology, Michigan State University, East Lansing, MI, 48824, USA.

Sandra A O'Toole (SA)

Sydney Medical School, University of Sydney, Sydney, NSW, 2006, Australia.
The Kinghorn Cancer Centre and Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW, 2010, Australia.

Ivan Topisirovic (I)

Lady Davis Institute for Medical Research, McGill University, Montréal, QC, H3T 1E2, Canada.
Department of Oncology, McGill University, Montréal, QC, H3A 1A3, Canada.

William J Muller (WJ)

Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montréal, QC, H3A 1A3, Canada. william.muller@mcgill.ca.
Department of Biochemistry, McGill University, Montréal, QC, H3A 1A3, Canada. william.muller@mcgill.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH